Drug Profile
ATL 844
Latest Information Update: 30 Apr 2012
Price :
$50
*
At a glance
- Originator PGxHealth
- Class
- Mechanism of Action Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2011 Discontinued - Phase-II for Asthma in USA (PO)
- 31 Dec 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)